Qlaira: first COC licensed for heavy menstrual bleeding

In: Prescriber · 2011 · vol. 22(22) , pp. 15–18 · doi:10.1002/psb.837 · W2007783161
article OA: closed CC0
View on OpenAlex View at publisher

Abstract

Abstract Qlaira (estradiol valerate plus dienogest) is the first combined oral contraceptive to gain a licence for the treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Dr Paula Briggs discusses its place in the treatment of heavy menstrual bleeding. Copyright © 2011 Wiley Interface Ltd

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T04:02:56.979793+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC0 · commercial use OK